Activation of CD95L fusion protein prodrugs by tumor-associated proteases

Cell Death and Differentiation

Volumn 14, Issue 4, 2007, Pages 765-774

  Watermann, I ^a   Gerspach, J ^a   Lehne, M ^b   Seufert, J ^b   Schneider, B ^a   Pfizenmaier, K ^a   Wajant, H ^b  

^a UNIVERSITY OF STUTTGART   (Germany)

^b UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOTRANSFERASE; ANTINEOPLASTIC AGENT; CASPASE 3; FAS LIGAND; FAS LIGAND SC36 FUSION PROTEIN; MATRIX METALLOPROTEINASE; MEMBRANE ANTIGEN; NEUTRALIZING ANTIBODY; PRODRUG; UNCLASSIFIED DRUG; UROKINASE;

AMINOTRANSFERASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; CROSS LINKING; DRUG ACTIVATION; DRUG DESIGN; DRUG EFFICACY; DRUG SAFETY; DRUG SCREENING; ENZYME ACTIVITY; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; TARGET CELL; TOXICITY TESTING; TUMOR XENOGRAFT; XENOTRANSPLANTATION;

ANIMALS; ANTIGENS, CD95; ANTIGENS, NEOPLASM; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL MEMBRANE; FAS LIGAND PROTEIN; FIBROSARCOMA; HUMANS; MATRIX METALLOPROTEINASE 2; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; PRODRUGS; RECOMBINANT PROTEINS; TOXICITY TESTS, CHRONIC; TUMOR CELLS, CULTURED; TUMOR MARKERS, BIOLOGICAL;

EID: 33947399851     PISSN: 13509047     EISSN: 14765403     Source Type: Journal    
DOI: 10.1038/sj.cdd.4402051     Document Type: Article

References (15)

1. Debatin KM, Krammer PH. Death receptors in chemotherapy and cancer. Oncogene 2004; 23: 2950-2966.
2. Igney FH, Krammer PH. Tumor counterattack: Fact or fiction? Cancer Immunol Immunother 2005; 54: 1127-1136.
3. Wajant H, Pfizenmaier K, Scheurich P. Non-apoptotic Fas signaling. Cytokine Growth Factor Rev 2003; 14: 53-66.
4. Wajant H, Gerspach J, Pfizenmaier K. Tumor therapeutics by design: targeting and activation of death receptors. Cytokine Growth Factor Rev 1 2005; 6: 55-76.
5. Schneider P, Holler N, Bodmer JL, Hahne M, Frei K, Fontana A et al. Conversion of membrane-bound Fas(CD95) ligand to its soluble form is associated with downregulation of its proapoptotic activity and loss of liver toxicity. J Exp Med 1998; 187: 1205-1213.
6. Samel D, Muller D, Gerspach J, Assohou-Luty C, Sass G, Tiegs G et al. Generation of a FasL-based proapoptotic fusion protein devoid of systemic toxicity due to cell-surface antigen-restricted activation. J Biol Chem 2003; 278: 32077-32082.
7. Gerspach J, Muller D, Munkel S, Selchow O, Nemeth J, Noack M et al. Restoration of membrane TNF-like activity by cell surface targeting and matrix metalloproteinase-mediated processing of a TNF prodrug. Cell Death Differ 2006; 13: 273-284.
8. Wuest T, Gerlach E, Banerjee D, Gerspach J, Moosmayer D, Pfizenmaier K. TNF-selectokine: A novel prodrug generated for tumor targeting and site-specific activation of tumor necrosis factor. Oncogene 2002; 21: 4257-4265.
9. Schmidt A, Muller D, Mersmann M, Wuest T, Gerlach E, Garin-Chesa P et al. Generation of human high-affinity antibodies specific for the fibroblast activation protein by guided selection. Eur J Biochem 2001; 268: 1730-1738.
10. Garin-Chesa P, Old LJ, Rettig WJ. Cell surface glycoprotein of reactive stromal fibroblasts as a potential antibody target in human epithelial cancers. Proc Natl Acad Sci USA 1990; 87: 7235-7239.
11. Holler N, Kataoka T, Bodmer JL, Romero P, Romero J, Deperthes D et al. Development of improved soluble inhibitors of FasL and CD40L based on oligomerized receptors. J Immunol Methods 2000; 237: 159-173.
12. Kammerer RA, Schulthess T, Landwehr R, Lustig A, Fischer D, Engel J. Tenascin-C hexabrachion assembly is a sequential two-step process initiated by coiled-coil alpha-helices. J Biol Chem 1998; 273: 10602-10608.
13. Brock B, Garin-Chesa P, Behrle E, Park JE, Rettig WJ, Pfizenmaier K et al. Species-crossreactive scFv against the tumor stroma marker 'fibroblast activation protein' selected by phage display from an immunized FAP-/- knock-out mouse. Mol Med 2001; 7: 461-469.
14. Wajant H. CD95L/FasL and TRAIL in tumour surveillance and cancer therapy. Cancer Treat Res 2006; 130: 141-165.
15. Asher A, Mule JJ, Reichert CM, Shiloni E, Rosenberg SA. Studies on the anti-tumor efficacy of systemically administered recombinant tumor necrosis factor against several murine tumors in vivo. J Immunol 1987; 138: 963-974.